IN8Bio is a clinical-stage, oncology-focused biotechnology company using ?d T cells against solid and hematological tumors. Its pipeline is built on the DeltEx platform & drug-resistant immunotherapy (DRI) technology which have produced clinical candidates targeting leukemia & GBM. INB-100 is evaluating leukemia in a Ph1 study, while INB-200 & INB-400 are Ph1 and Ph2 assets evaluating GBM. As of September 2024, the only active program is in AML. INB-100 is an allogeneic DeltEx-produced cell therapy for leukemia patients undergoing HSCT transplant. Leukemia patients see a high rate of recurrence which may be effectively treated by INB-100. INB-200 is a DeltEx DRI product completing Ph1 studies in GBM. INB-400 is the successor to INB-200. It is an autologous DeltEx DRI product to treat newly diagnosed and recurrent GBM. The DRI genetic modification allows the cells to resist chemotherapy and persist in the tumor microenvironment. While active clinical studies target leukemia, we see DeltEx DRI as a platform that can expand to additional initiations. Combination studies with chemotherapy, checkpoint and PARP inhibitors may emerge in future iterations.
